Law360, New York (June 10, 2009, 12:00 AM EDT) -- Giving the U.S. Food and Drug Administration the authority to approve generic versions of biologic drugs would be an effective way to cut costs for the pricey treatments and introduce competition into the biologics market, a report released Wednesday by the Federal Trade Commission said.
In the report, the FTC weighed in on the growing debate over the best way to bring generic versions of biologic drugs — known as follow-on-biologics, or FOBs — to consumers.
Biologic drugs are produced from living cell cultures rather than...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.